Результаты поиска

Biphosphonates-associated osteonecrosis of the jaw: the role of gene-environment interaction.

Biphosphonate (BPN) are widely used in clinics to treat metastatic cancer and osteoporosis thus representing a problem not only for patients but also for workers involved in their preparation and administration. A similar exposure occurred years ago in match-making workers undergoing bone alterations similar to those consequent to BPN exposure. Osteonecrosis of the jaw (ONJ) is a main adverse effect related to BPN administration, which is performed in millions of patients worldwide for osteoporosis and cancer therapy, thus representing an emerging problem in public health. In susceptible patie

Совпадение в полном тексте источника
… Semin Arthritis Rheum. 2002;32:94–124. 47. Izzotti A, Cartiglia C, Longobardi M, et al. Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke. FASEB J. 2004;18:1559–1561. doi: 10.1096/fj.04-1877fje. 48. Bagan JV, Jiménez Y, Gómez D, et al. …

Иммуномодулирующие свойства месенхимальных стволовых клеток и их внеклеточных везиков: потенциальные клинические применения в аутоиммунных заболеваниях.

Мезенхимальные стволовые клетки (МСЦ)/мезенхимические стромальные клетки и их внеклеточные везикли (ЭМ), в частности экзосомы, появились в качестве терапевтических кандидатов в регенеративной медицине в силу их многопотенции, низкой иммуногенности и обширных иммунодуляторных свойств. В настоящем описательном обзоре содержится сводная информация об иммуномодуляции МСЦ- и МСЦ-В и о ее потенциале в плане перевода на другие языки. four основные аутоиммунные заболевания: множественный склероз (МС), тип 1 - сахарный диабет (T1D), системный волшебный эриматоз (SLE) и ревматоидный артрит (RA).Механист

Совпадение в аннотации оригинала
Mesenchymal stem cells (MSCs)/mesenchymal stromal cells and their extracellular vesicles (EVs), particularly exosomes, have emerged as thera … s: multiple sclerosis (MS), type 1 diabetes mellitus (T1D), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Mechanistically, MSCs regulate both innate and adaptive immune cell populations, modulate pro- and anti-inflammatory cytokine secretion, downregulate pro-inflammatory Th1/Th17 responses, and promote regulatory phenotypes, includ …

How to Choose the Right Treatment for Membranous Nephropathy

Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of patients develop end-stage renal disease. The discovery of autoantibodies such as phospholipase A2 receptor 1, antithrombospondin and neural epidermal growth factor-like 1 protein has greatly helped us to understand the pathogenesis and enable the diagnosis of this disease and to guide its treatment. Depending on the complications of nephrotic syndrome, patients with this disease receive supportive treatment with diuretics, AC

Совпадение в полном тексте источника
… Rheum. Dis. 2013;72:1496–1502. doi: 10.1136/annrheumdis-2012-201956. 65. van Vollenhoven R.F., Emery P., Bingham C.O., Keystone E.C., Fleischmann R., Furst D.E., Macey K., Sweetser M., Kelman A., Rao R. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. … Rheum. Dis. 2018;1:1163–1172. doi: 10.1111/1756-185X.13321. 109. Zilberman T., Zahavi T., Osadchy A., Nacasch N., Korzets Z. Membranous Nephropathy Associated with Sarcoidosis: A Primary or Secondary Glomerulopathy? Isr. Med. Assoc. J. 2014;16:390–392. 110. …

B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19th century, but only the discovery of aquaporin-4 autoantibodies in a major subset of affected patients in 2004 led to a fundamentally revised disease concept: Neuromyelits optica spectrum disorders (NMOSD) are now considered autoantibody-mediated autoimmune diseases, bringing the pivotal pathogenetic role of B cells and plasma cells into focus. Not long ago, there was no approved medication for this deleterious disease and off-label therapies were the only treatment options for affected patient

Совпадение в полном тексте источника
… Arthritis Rheum. 2011;63:1255–1264. doi: 10.1002/art.30242. 159. Choi I.A., Lee S.J., Park W., Park S.H., Shim S.C., Baek H.J., Yoo D.H., Kim H.A., Lee S.K., Lee Y.J., et al. Effects of tocilizumab therapy on serum interleukin-33 and interleukin-6 levels in patients with rheumatoid arthritis. …

The burden of disease in Spain: results from the global burden of disease study 2010.

BackgroundWe herein evaluate the Spanish population's trends in health burden by comparing results of two Global Burden of Diseases, Injuries, and Risk Factors Studies (the GBD studies) performed 20 years apart.MethodsData is part of the GBD study for 1990 and 2010. We present results for mortality, years of life lost (YLLs), years lived with disability, and disability-adjusted life years (DALYs) for the Spanish population. Uncertainty intervals for all measures have been estimated.ResultsNon-communicable diseases accounted for 3,703,400 (95% CI 3,648,270-3,766,720) (91.3%) of 4,057,400 total

Совпадение в полном тексте источника
… Ann Rheum Dis. 2014;73:975–981. doi: 10.1136/annrheumdis-2013-204631. 20. Min JA, Lee CU, Lee C. Mental health promotion and illness prevention: a challenge for psychiatrists. Psychiatry Investig. 2013;10:307–316. doi: 10.4306/pi.2013.10.4.307. 21. … Ann Rheum Dis. 2014;73:968–974. doi: 10.1136/annrheumdis-2013-204428. 32. Hopman WM, Harrison MB, Coo H, Friedberg E, Buchanan M, VanDenKerkhof EG. Associations between chronic disease, age and physical and mental health status. Chronic Dis Can. 2009;29:108–116. 33. Starfield B, Shi L, Macinko J. …

Infiltrative and inflammatory systemic disorders involving the pituitary gland.

The hypothalamic-pituitary region can be affected by a wide and heterogeneous group of infiltrative and inflammatory disorders, including granulomatous, histiocytic, storage, infectious, non-pituitary neoplastic, and autoimmune or inflammatory conditions collectively grouped as hypophysitis. Although individually rare, these disorders are increasingly recognized due to growing awareness, wider use of pituitary imaging, and the emergence of immune checkpoint inhibitor-induced hypophysitis. They typically present with hypopituitarism (often including arginine vasopressin deficiency, which, parti

Совпадение в полном тексте источника
… Ann Rheum Dis 74:1171–1177. 10.1136/annrheumdis-2014-206605 34. Wallace ZS, Mattoo H, Mahajan VS et al (2016) Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford) 55:1000–1008. 10.1093/rheumatology/kev438 35. … Ann Rheum Dis 74:1596–1602. 10.1136/annrheumdis-2013-204924 84. Courtillot C, Laugier Robiolle S, Cohen Aubart F et al (2016) Endocrine Manifestations in a Monocentric Cohort of 64 Patients With Erdheim-Chester Disease. J Clin Endocrinol Metab 101:305–313. 10.1210/jc.2015-3357 85. …

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study.

Background: It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and safety of biologic drugs are well-documented in clinical trials and in real-life studies. However, there is limited evidence on the safety of the use of biologic treatments in cancer patients with psoriasis, and the use of this therapeutic class in patients with a pre-existing or concomitan

Совпадение в полном тексте источника
… Rheum. Dis. 2010;69:400–408. doi: 10.1136/ard.2009.117762. 56. Patel R.V., Clark L.N., Lebwohl M., Weinberg J.M. Treatments for psoriasis and the risk of malignancy. J. Am. Acad. Dermatol. 2009;60:1001–1017. doi: 10.1016/j.jaad.2008.12.031. 57. … Rheum. Dis. 2005;64:1414–1420. doi: 10.1136/ard.2004.033241. 58. …

Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.

Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B-cell malignancies has proven successful, and there is strong rationale for the potential benefits of BTK inhibitors in some autoimmune and allergic conditions, including immune-mediated dermatological diseases. However, the established risk-to-benefit profile of "first-generation" BTK inhibitors cannot be extrapolated to these emerging, non-oncological, indications. "Next-generation" BTK inhibitors such as remibrutinib

Совпадение в полном тексте источника
… Ann Rheum Dis . 2015 ; 74 ( 8 ): 1603 ‐ 1611 . 24764451 10.1136/annrheumdis-2013-204143 10 de Gorter DJ , Beuling EA , Kersseboom R , et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine‐controlled B cell migration and homing . … Ann Rheum Dis . 2012 ; 71 ( 11 ): 1833 ‐ 1838 . 22550315 10.1136/annrheumdis-2011-200831 PMC3465857 115 Blair HA , Duggan ST . Belimumab: a review in systemic lupus erythematosus . Drugs . 2018 ; 78 ( 3 ): 355 ‐ 366 . 29396833 10.1007/s40265-018-0872-z 116 Makurvet FD . …

New strategies and perspectives on managing IgA nephropathy.

IgA nephropathy is an inflammatory renal disease characterised by the deposition of IgA in the glomerular mesangium and is the most commonly reported primary glomerulonephritis worldwide. Thirty to forty percent of patients with the disease develop progressive renal function decline, requiring renal replacement therapy within two decades of diagnosis. Despite this, accurate individual risk stratification at diagnosis and predicting treatment response remains a challenge. Furthermore, there are currently no disease specific treatments currently licensed to treat the condition due to long standi

Совпадение в полном тексте источника
… Isenberg D Gordon C Licu D Copt S Rossi CP Wofsy D Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) Ann Rheum Dis 2015 74 11 2006 2015 24951103 10.1136/annrheumdis-2013-205067 PMC4680140 … Taylor PC Genovese MC Greenwood M Ho M Nasonov E Oemar B OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy Ann Rheum Dis 2015 74 12 2123 2129 25074688 10.1136/annrheumdis-2014-205361 80. …

Ход работы сессии 29th Европейский конгресс педиатрии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Ann Rheum Dis 2018;77:819-28. Trincianti C, Van Dijkhuizen EHP, Alongi A, et al.; PRINTO. Arthritis Rheumatol 2021;73:1966-75. O05 Incidence of uveitis and uveitis related complications in children with juvenile idiopathic arthritis: results from the childhood arthritis prospective study J. …

Congestive heart failure associated with POEMS syndrome that was adequately distinguished from cardiac amyloidosis: a case report and literature review.

Congestive heart failure (CHF) is a common complication in patients with AL amyloidosis but is rare in another plasma cell dyscrasia, POEMS syndrome. A 52-year-old man developed POEMS syndrome with a solitary plasmacytoma complicated by CHF mimicking cardiac amyloidosis (CA). His neurological symptoms and CHF did not improve after radiotherapy (50 Gy) targeting the plasmacytoma. Based on typical findings of noninvasive examinations such as elevated serum NT-proBNP (12,631 pg/mL), a pseudo-infarct pattern on electrocardiography, interventricular septal thickening with a granular sparkling appea

Совпадение в полном тексте источника
… Arthritis Rheum 2006 ; 54 : 2015 - 21 . 10.1002/art.21902 16732553 …

Potential diagnostic value of PD-1 in peripheral blood mononuclear cells of postmenopausal osteoporosis patients.

BACKGROUND: Postmenopausal osteoporosis (PMOP) is an estrogen deficiency-induced skeletal disorder. Bone mineral density (BMD) testing is the gold standard for diagnosing osteoporosis. However, its sensitivity for fracture risk assessment is low. Programmed cell death protein 1 (PD-1) is a key immune checkpoint molecule implicated in the pathophysiology of bone remodeling, but its role in osteoporosis has not yet been explored. Thus, this study aimed to assess the expression and diagnostic utility of PD-1 in PMOP. METHODS: A total of 56 patients with PMOP and 37 postmenopausal healthy control

Совпадение в полном тексте источника
… Arthritis Rheum . 2010 ; 62 ( 7 ): 1870 ‐ 1880 . 20506224 10.1002/art.27500 18 Liu C , Jiang J , Gao L , et al. Soluble PD‐1 aggravates progression of collagen‐induced arthritis through Th1 and Th17 pathways . …

The IL-17 family in diseases: from bench to bedside.

The interleukin-17 (IL-17) family comprises six members (IL-17A-17F), and recently, all of its related receptors have been discovered. IL-17 was first discovered approximately 30 years ago. Members of this family have various biological functions, including driving an inflammatory cascade during infections and autoimmune diseases, as well as boosting protective immunity against various pathogens. IL-17 is a highly versatile proinflammatory cytokine necessary for vital processes including host immune defenses, tissue repair, inflammatory disease pathogenesis, and cancer progression. However, ho

Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Background: Since the 1990s, transplantations of hematopoietic and mesenchymal stem cells (HSCT and MSCT) and dendritic cell (DCT) have been investigated for the treatment of neurological autoimmune disorders (NADs). With the growing number of transplanted patients, awareness of neuroimmunolgical complications has increased. Therefore, an overview of SCT for the most common NADs and reports of secondary immunity after SCT is provided. Methods: For this narrative review, a literature search of the PubMed database was performed. A total of 86 articles reporting on different SCTs in NADs and 61 a

Совпадение в полном тексте источника
… Arthritis Rheum. 1997;40:1712–1715. doi: 10.1002/art.1780400923. 6. Marmont A.M., van Lint M.T., Gualandi F., Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997;6:545–548. doi: 10.1177/096120339700600613. 7. … Rheum. Dis. 2000;59:236–238. doi: 10.1136/ard.59.3.236. 102. Lehnhardt F.G., Scheid C., Holtik U., Burghaus L., Neveling M., Impekoven P., Rüger A., Hallek M., Jacobs A.H., Rubbert A. …

Biological Role, Mechanism of Action and the Importance of Interleukins in Kidney Diseases.

Each year, the number of patients who are diagnosed with kidney disease too late is increasing, which leads to permanent renal failure. This growing problem affects people of every age, sex and origin, and its full etiopathogenesis is not fully understood, although the involvement of genetic susceptibility, infections, immune disorders or high blood pressure is suggested. Difficulties in making a correct and quick diagnosis are caused by the lack of research on early molecular markers, as well as educational and preventive activities among the public, which leads to the late detection of kidne

Совпадение в полном тексте источника
… Rheum. Dis. 2017;20:996–1001. doi: 10.1111/1756-185X.13122. 28. Lipiec K., Adamczyk P., Świętochowska E., Ziora K., Szczepańska M. Angiotensinogen and Interleukin-18 as Markers of Chronic Kidney Damage in Children with a History of Hemolytic Uremic Syndrome. Physiol. … Arthritis Rheum. 2006;54:2722–2733. doi: 10.1002/art.22039. 132. Pelletier M., Girard D. Biological Functions of Interleukin-21 and Its Role in Inflammation. Sci. World J. 2007;7:1715–1735. doi: 10.1100/tsw.2007.275. 133. Lin P.-Y., Jen H.-Y., Chiang B.-L., Sheu F., Chuang Y.-H. …

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Real-world evidence (RWE) is emerging as a fundamental component of the post-marketing evaluation of medicinal products. Even though the focus on RWE studies has increased in Colombia, the availability of secondary data sources to perform this type of research is not well documented. Thus, we aimed at identifying and characterizing secondary data sources available in Colombia. We performed a systematic literature review on PubMed, EMBASE, and VHL using a combination of controlled vocabulary and keywords for the concepts of electronic health records, epidemiologic studies and Colombia. A total

Совпадение в полном тексте источника
… Ann Rheum Dis, BMJ Publishing Group Ltd and European League Against Rheumatism. 2017;1158. 76. Jiménez JG, Balparda JK, Castrillón DM, et al. Characterization of hospital‐acquired infections in a University Hospital in Colombia: january 2005‐july 2009. Int J Infect Dis. 2010;14:e260‐e261. 77. … Ann Rheum Dis. 2016;75:711.4‐712. 245. Triana L, Triana C, Barbato C, Liposuction ZM. Liposuction: 25 years of experience in 26,259 patients using different devices. Aesthetic Surg J. 2009;29(6):509‐512. 246. Urcuqui LA, Castro MX, Medina D, Aristizabal P, Bravo LE, Ramirez O. …

A systematic review and meta-analysis of herpes zoster risk in adults with immunocompromised conditions and autoimmune diseases in Asia-Pacific.

Asia-Pacific (APAC) faces an increasing burden of herpes zoster (HZ) over time. The risk of HZ and its complications are increased in immunocompromised (IC) patients and those with autoimmune diseases (AID). Our study aimed to synthesize evidence on the epidemiological burden of HZ and its complications among the general adult population and patients with IC/AID conditions in APAC. Following a systematic literature review, we performed meta-analyses for outcomes where ≥3 studies met the inclusion criteria. Of the 271 articles identified, 75 were included for meta-analysis. We found a high burd

Совпадение в полном тексте источника
… Int J Rheum Dis. 2019;22(7):1239–1246. doi: 10.1111/1756-185x.13585. Epub 2019/05/16. PubMed PMID: 31090187. 36. Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, Nam S-H, Kwon JH, Kim HJ, Sohn SK, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. … Int J Rheum Dis. 2018;21(9):1670–1677. Epub 2018/04/19. doi: 10.1111/1756-185x.13300. PubMed PMID: 29667330. 41. Sun X, Wei Z, Lin H, Jit M, Li Z, Fu C. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: data from an integrated health care network. …

ЦАРТ клетки в качестве новой терапевтической стратегии для множественных склерозов и других нейроиммунных расстройств.

В качестве трансформационного подхода к лечению множественных склерозов (MS) и других нейроиммунных расстройств, таких, как расстройства спектра нейромиелита (NMOSD), миелин олигодендроцита гликпротеина, связанных с антителами (MOGAD), и миастения гравис (MG), наряду с рядом других редких нейроиммунологических заболеваний, которые в настоящее время оцениваются в исследованиях, посвященных сочувствию или ранней фазе. Отчасти эти условия обусловлены автоматически реактивными клетками B, вызывающими хроническое воспаление и прогрессивное повреждение тканей. Несмотря на то, что нынешняя иммунодуля

Совпадение в полном тексте источника
… Ann Rheum Dis. 2024;83(10):1304–14. 56. Auth J, Müller F, Völkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2025;7(2):e83–93. 57. Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. … Ann Rheum Dis. 2024 Oct 21;83(11):1597-1598. 10.1136/ard-2024-226017. PMID: 38937071. . 78. Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, et al. Treatment of concomitant myasthenia Gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. …

Mesenchymal stem cells lineage and their role in disease development.

BackgroundMesenchymal stem cells (MSCs) are widely dispersed in vivo and are isolated from several tissues, including bone marrow, heart, body fluids, skin, and perinatal tissues. Bone marrow MSCs have a multidirectional differentiation potential, which can be induced to differentiate the medium in a specific direction or by adding specific regulatory factors. MSCs repair damaged tissues through lineage differentiation, and the ex vivo transplantation of bone marrow MSCs can heal injured sites. MSCs have different propensities for lineage differentiation and pathological evolution for differen

Совпадение в полном тексте источника
… Arthritis Rheum. 2004;50(3):817–27. Kaplan MS, Hinds JW. Neurogenesis in the adult rat: electron microscopic analysis of light radioautographs. Science. 1977;197(4308):1092–4. Kato Y, Matsuura T, Watanabe H. … Arthritis Rheum. 2002;46(3):704–13. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. …

Целевая экспериментальная эмуляция карфилзомибной безопасности у пациентов с повторной/отходной миеломой с использованием общенациональных данных наблюдений в Корее.

ЦЕЛЬ: Карфилзомиб, который обычно используется для повторного/изъятия множественной миэломы (RRMM), связан с различными неблагоприятными явлениями в ходе выборочно контролируемых испытаний (RCT). Вместе с тем необходимы реальные данные о безопасности для более разнообразного населения, поскольку карфилзомиб получил ускоренное одобрение. Цель этого исследования заключалась в том, чтобы оценить безопасность карфилзомиба в Корее путем сопоставления новых пользователей KRd (карфилзомиба, линалидомида и дексаметазона) с Rd (lenalidomide и dexamethasone) с использованием общенациональной базы данных

Совпадение в полном тексте источника
… Front Cardiovasc Med 8:735466. 10.3389/fcvm.2021.735466 34646873 10.3389/fcvm.2021.735466 PMC8503541 Zhao SS Lyu H Solomon DH Yoshida K Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework Ann Rheum … Ann Rheum Dis 79(7):883–890. 10.1136/annrheumdis-2020-217200 32381560 10.1136/annrheumdis-2020-217200 PMC8693471 …